Prolaris has been proven to predict disease specific mortality in prostate cancer patients following needle biopsy. In a study of men with conservatively managed, localized prostate cancer, with an end point of disease specific mortality, Prolaris was predictive of disease aggressiveness.
Prolaris testing is also particularly well-suited for post-prostatectomy patients to better estimate the risk of biochemical recurrence (BCR). Managing patients before and after BCR is a complex issue.
Learn how to implement Prolaris testing in your practice today.
In this video series, Dr. Michael Brawer, Medical Director of Myriad’s Urology Business Unit, addresses several questions often raised by payers and physicians alike. To hear your concern answered, click on the square corresponding to your specific question. To increase the video size to full screen, click the icon in the bottom right corner of each square — or pause the response half way through and move onto the next question if you want to learn more.
Start Testing With Prolaris In Your Practice Today
Adding a Prolaris ScoreTM to your diagnosis is easy. Learn more about the ordering process for Prolaris and see how you can help your patients receive a more personalized prostate cancer treatment experience.
After you review the ordering process, you will be able to quickly download and print our Prolaris Test Request forms and start testing immediately.
Communicating the risks of prostate cancer with your patients is nothing new to you, but how do you seamlessly integrate the added benefit of their Prolaris risk into your discussions? We can help you provide clarification around your patients’ common concerns.